Moderna, Merck mRNA Cancer Vaccine Prevents Melanoma From Returning in Trial

Hope for cancer patients as scientists report breakthrough in personalised cancer vaccines

Merck and Moderna said the vaccine helped prevent the return and spread of melanoma in a large trial involving more than 1,000 patients. The post Hope for cancer patients as scientists report breakthrough in personalised cancer vaccines appeared first on Premium Times Nigeria.

Notable healthcare headlines for the week: Moderna, Merck and Twist Bioscience in focus

Weekly healthcare stock market recap: S&P 500 Health Care jumps as Moderna surges on cancer vaccine data; key winners/losers and catalysts—read now.

How a personalised cancer vaccine could cut risk of death by half

Personalised cancer vaccine intismeran, combined with Keytruda, cut death risks in melanoma. Know how it works and what the results mean for India.

Why Is MRNA Stock Up Today? Moderna Closes 177% Higher

A week ago, 14 out of 15 Wall Street analysts covering Moderna rated the stock either Hold or Sell. The average price target sat at $48.92. On August 19, the stock closed at $174.38. That is not a typo. Moderna (MRNA) gained 177% in a single session, on trading volume of 185.1 million shares, roughly 19 times its three-month average. The trigger: Moderna and Merck announced that their individualized mRNA cancer therapy, intismeran autogene, met …